ライフサイエンスコーパス: moderate disease

1 ells and similar low RNA levels (2 patients, moderate disease).

2 se of platelet transfusions (41 with mild or moderate disease).

3 ility to predict the transition from mild to moderate disease.

4 were significantly elevated in patients with moderate disease.

5 e disease had higher viremia than those with moderate disease.

6 was 24% for severe periodontitis and 61% for moderate disease.

7 ions in this cohort of patients with mild-to-moderate disease.

8 n higher odds of epilepsy compared with mild/moderate disease.

9 even in younger patients and those with only moderate disease.

10 n compared with the prevalence of severe and moderate disease.

11 190 and 541-560, and several others elicited moderate disease.

12 ging from 0.5 to 3, corresponding to mild to moderate disease.

13 thotrexate are effective in treating mild to moderate disease.

14 dontitis was better for severe compared with moderate disease.

15 Disease classification included normal to moderate disease (0%-50% stenosis), severe stenosis (> 5

16 I, 2.9-13.4; p = 0.003) than those with mild/moderate disease (1.6% increase; 95% CI, -2.2-5.4; p = 0

17 s had severe disease (>70% stenosis), 12 had moderate disease (50%-70% stenosis), 46 had mild disease

18 all disease was 78.9% (95% CI, 69.7%-85.3%); moderate disease, 92% (50-500 lesions) and 100% (clinici

19 In children with mild to moderate disease, a reduction of zidovudine to 90 mg/m2/

20 to low disease activity (DAS/DAS28/CDAI) or moderate disease activity (SDAI).

21 f patients receiving MTX monotherapy who had moderate disease activity and a poor prognosis or high d

22 nt was more effective in achieving a good or moderate disease activity response at 24 weeks than was

23 e-escalation study, 16 patients with mild-to-moderate disease activity were assigned to receive 1 of

24 d for 21%, 23%, and 34% of 149 patients with moderate disease activity within 3, 6, and 12 months, re

25 suggests that for this population of mild-to-moderate disease activity, the PDAI captures more variab

26 ctively, of the patient meeting criteria for moderate disease activity.

27 Patients spent a mean of 3.4 years with mild-moderate disease and 3.4 years with severe disease befor

28 to be effective in the treatment of mild to moderate disease and nonsteroidal anti-inflammatory drug

29 In tooth sites with mild to moderate disease and severe disease (n = 183, intent-to-

30 there are no medical consequences to having moderate disease and that disease stage transitions can

31 reased risk of mortality even for those with moderate disease and the inability to predict the transi

32 conclusion, (31)P MRS can separate mild from moderate disease and these 2 groups from cirrhosis.

33 ding on probing (slight disease), 3 to 6 mm (moderate disease), and >6 mm (severe disease).

34 d pulmonary disease, 19% in patients who had moderate disease, and 26% in patients who had severe dis

35 y, 6 (4.6%) had mild disease, 98 (74.8%) had moderate disease, and 27 (20.6%) severe manifestations o

36 (PDE) ratios for the control, mild disease, moderate disease, and cirrhosis groups: 0.15 +/- 0.01, 0

37 ly age, especially for those with severe and moderate disease, and that BMI is an important, potentia

38 ons in more severe disease; phototherapy for moderate disease; and systemic agents including photoche

39 thropoiesis, or hemoglobin between severe or moderate disease, but multiple linear regression showed

40 but were also elevated in untreated, mild-to-moderate disease compared with healthy control subjects.

41 when compared with controls, whereas mild-to-moderate disease does not suppress contact sensitization

42 Women who have a mild to moderate disease flare while on optimized 5-ASA or thiop

43 In mild-moderate disease, for participants at or above the media

44 Even patients with mild/moderate disease frequently suffer adverse effects from

45 conversion of severe hemophilia B to mild or moderate disease in 6 adult males who underwent intraven

46 Second- and third-wave viruses caused moderate disease in ferrets, transmitted efficiently to

47 evere hemophilia A in some patients and mild/moderate disease in others.

48 from asthmatic subjects with stable mild and moderate disease is an artifact of tissue sampling and i

49 ad greater protein excretion than those with moderate disease (< or = 10 cysts; n = 49) (4.4+/-0.5 ve

50 In moderate disease, no independent predictors of hepcidin

51 ease at baseline, those who reported mild or moderate disease on follow-up had significantly greater

52 nfected with influenza virus display mild-to-moderate disease phenotypes and recover within a few wee

53 doses are economically optimal under low or moderate disease pressure, or where other control measur

54 effectiveness in population groups with low/ moderate disease prevalence (< or =70%); as expected, di

55 Viral evolution in individuals with rapid or moderate disease progression showed selection favoring n

56 nucleotide polymorphisms (SNPs) have weak-to-moderate disease risks, genetic risk prediction models b

57 sease (CAD angiographic score of 0), mild-to-moderate disease (score of 1 to 3), and severe disease (

58 5 days, and the SAP6 rescuant reestablished moderate disease severity.

59 roduced protein derived from tick saliva, in moderating disease severity.

60 Moderate disease showed retina-wide rod > cone dysfuncti

61 rough mild cognitive impairment to early and moderate disease stages).

62 x, Stanford class, and incidence of at least moderate disease (Stanford class > or = 3) were measured

63 old greater in patients with asymptomatic or moderate disease than in those with severe disease.

64 However, the BCa11-3 mutant produced moderate disease that was significantly less severe than

65 of motor control in individuals with mild to moderate disease through experience-dependent neuroplast

66 that of seasonal influenza viruses, mild-to-moderate disease was observed in infected mice and ferre

67 35% predicted), and 11 patients with mild to moderate disease were studied.

68 years, respectively, were estimated to have moderate disease, which highlights the potential benefit

69 would change when subjects improved to mild-moderate disease with controller medication treatment.

70 moderate-severe asthma who improved to mild-moderate disease with controller treatment, rescue beta-

71 esents an important strategy to consider for moderating diseases with altered endothelial integrity,

72 iagnostic challenge in patients with mild to moderate disease, with current imaging modalities being